MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in November 2011:
Credit Suisse 2011 Healthcare Conference
Thursday, November 10, at 4:00 p.m. MT in Phoenix
Lazard Capital Markets 8th Annual Healthcare Conference
Wednesday, November 16, at 10:30 a.m. ET in New York
A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX® is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
|
CONTACTS: |
||
|
Nicole Foderaro |
Lisa Borland |
|
|
WCG |
MAP Pharmaceuticals, Inc. |
|
|
(415) 946-1058 |
650-386-3122 |
|
SOURCE MAP Pharmaceuticals, Inc.